Galmed Pharmaceuticals Ltd - Asset Resilience Ratio

Latest as of December 2025: 76.08%

Galmed Pharmaceuticals Ltd (GLMD) has an Asset Resilience Ratio of 76.08% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check how strategically is Galmed Pharmaceuticals Ltd's equity deployed to assess the company's strategic physical and investment asset allocation.

Liquid Assets

$14.17 Million

Cash + Short-term Investments

Total Assets

$18.63 Million

All company assets

Resilience Assessment

Very High

Financial Resilience Level

Asset Resilience Ratio Trend (2014–2025)

This chart shows how Galmed Pharmaceuticals Ltd's Asset Resilience Ratio has changed over time. See Galmed Pharmaceuticals Ltd (GLMD) net asset quality to measure how much of total assets are equity-financed.

Liquid Assets Composition Over Time

This chart breaks down Galmed Pharmaceuticals Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Galmed Pharmaceuticals Ltd (GLMD) total market value.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	$0.00	0%
Short-term Investments	$14.17 Million	76.08%
Total Liquid Assets	$14.17 Million	76.08%

Asset Resilience Insights

Very High Liquidity: Galmed Pharmaceuticals Ltd maintains exceptional liquid asset reserves at 76.08% of total assets.
This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
The company has significant short-term investments, indicating active treasury management.

Galmed Pharmaceuticals Ltd Industry Peers by Asset Resilience Ratio

Compare Galmed Pharmaceuticals Ltd's asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
Biomarin Pharmaceutical Inc NASDAQ:BMRN	Biotechnology	0.00%
Cyclacel Pharmaceuticals Inc NASDAQ:CYCC	Biotechnology	-55.36%
Krystal Biotech Inc NASDAQ:KRYS	Biotechnology	23.06%
Verona Pharma PLC ADR NASDAQ:VRNA	Biotechnology	0.00%
Centessa Pharmaceuticals PLC ADR NASDAQ:CNTA	Biotechnology	33.37%
Beijing Tiantan Biological Products Corp Ltd SHG:600161	Biotechnology	8.08%
Hebei Changshan Biochem Pharma SHE:300255	Biotechnology	-0.03%
BB Biotech AG SW:BION	Biotechnology	0.05%

Annual Asset Resilience Ratio for Galmed Pharmaceuticals Ltd (2014–2025)

The table below shows the annual Asset Resilience Ratio data for Galmed Pharmaceuticals Ltd.

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
2025-12-31	76.08%	$14.17 Million	$18.63 Million	+18.35pp
2024-12-31	57.72%	$10.68 Million	$18.50 Million	-1.09pp
2023-12-31	58.82%	$9.78 Million	$16.63 Million	-12.25pp
2022-12-31	71.06%	$11.77 Million	$16.56 Million	-16.17pp
2021-12-31	87.23%	$31.93 Million	$36.60 Million	+3.35pp
2020-12-31	83.88%	$43.94 Million	$52.38 Million	+6.67pp
2019-12-31	77.21%	$59.56 Million	$77.14 Million	+4.33pp
2018-12-31	72.88%	$66.03 Million	$90.60 Million	+42.46pp
2017-12-31	30.42%	$5.98 Million	$19.64 Million	-44.66pp
2016-12-31	75.08%	$12.35 Million	$16.45 Million	-2.59pp
2015-12-31	77.67%	$18.84 Million	$24.26 Million	+52.61pp
2014-12-31	25.06%	$8.25 Million	$32.92 Million	--

pp = percentage points

About Galmed Pharmaceuticals Ltd

NASDAQ:GLMD USA Biotechnology

Market Cap

$3.96 Million

Market Cap Rank

#29004 Global

#5873 in USA

Share Price

$0.60

Change (1 day)

-0.68%

52-Week Range

$0.47 - $2.33

All Time High

$3232.80